INSMED Inc
Insmed Incorporated (Nasdaq: INSM) is a biopharmaceutical company that develops and commercializes therapies for serious diseases, with commercial products and a clinical pipeline across Respiratory, Immunology & Inflammation, and Neuro & Other Rare. Its marketed respiratory products are ARIKAYCE, an inhaled amikacin… From the company’s description.
In fiscal 2025, INSMED Inc reported revenue of $606.42M, up 66.7% from fiscal 2024, and a net loss of $1.28B. Its operating margin was −205.6%, and operations used $935.01M in cash. Over the twelve months to Jun 30, 2026, revenue was $1.14B.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What INSMED Inc does
In the company’s own words
Insmed Incorporated (Nasdaq: INSM) is a biopharmaceutical company that develops and commercializes therapies for serious diseases, with commercial products and a clinical pipeline across Respiratory, Immunology & Inflammation, and Neuro & Other Rare. Its marketed respiratory products are ARIKAYCE, an inhaled amikacin treatment for certain adults with Mycobacterium avium complex lung disease, and BRINSUPRI, an oral treatment for non-cystic fibrosis bronchiectasis in patients 12 and older. The respiratory pipeline includes inhaled treprostinil palmitil (TPIP) and the antibody INS1148; brensocatib is also in development for hidradenitis suppurativa, while gene therapy candidates INS1201 and INS1202 target Duchenne muscular dystrophy and amyotrophic lateral sclerosis. The company’s preclinical research uses gene therapy, protein engineering, RNA end-joining, and other technologies. Insmed reports its business through three therapeutic areas rather than revenue-reporting segments. It licenses and acquires products and candidates, including brensocatib from AstraZeneca and INS1148 from Opsidio, and relies on external manufacturers for commercial and clinical supply. Its website is https://www.insmed.com/.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- BRIDGEWATER, NJ
- Fiscal year end
- December
- CIK
- 1104506
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns INSMED Inc — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in INSMED Inc · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · INSMED Inc’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do INSMED Inc and its peers compare on margins and cash generation over ten years?”
- “Where did five years of INSMED Inc's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in INSMED Inc's last four quarterly filings that the numbers alone won't show?”